Alnylam Pharmace. Stock
Price
Target price
€243.60
€243.60
-2.800%
-7.0
-2.800%
€274.83
23.08.24 / Tradegate
WKN: A0CBCK / Symbol: ALNY / Name: Alnylam Pharms / Stock / Biotechnology & Medical Research / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Alnylam Pharmace. Stock
A loss of -2.800% shows a downward development for Alnylam Pharmace..
The stock is an absolute favorite of our community with 46 Buy predictions and no Sell predictions.
As a result the target price of 274 € shows a slightly positive potential of 12.48% compared to the current price of 243.6 € for Alnylam Pharmace..
For the coming years our community has positive and negative things to say abot the Alnylam Pharmace. stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "EBIT growth" there were negative voices in the community.
Alnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Pros and Cons of Alnylam Pharmace. in the next few years
Pros
?
G***** c******* t* c**********
?
S********** s********
?
B****
Cons
?
C******** o* t** e**********
?
M***** P*******
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Alnylam Pharmace. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Alnylam Pharmace. | -2.800% | 0.123% | 12.830% | 39.041% | 37.627% | 44.270% | 231.293% |
| Ironwood Pharmaceuticals | -5.380% | 7.653% | -33.016% | -50.059% | -58.627% | -61.982% | -45.351% |
| Arrowhead Pharmaceuticals Inc. | 0.730% | 7.427% | -16.554% | -15.983% | -21.413% | -58.166% | -20.180% |
| Novocure Ltd | 0.650% | -0.770% | -6.881% | -41.606% | 12.820% | -86.008% | -80.601% |
Comments
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $400.00 price target on the stock.
Show more
Ratings data for ALNY provided by MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) was upgraded by analysts at The Goldman Sachs Group, Inc. from a "neutral" rating to a "buy" rating. They now have a $370.00 price target on the stock, up previously from $198.00.
Show more
Ratings data for ALNY provided by MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its price target raised by analysts at Royal Bank of Canada from $265.00 to $300.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for ALNY provided by MarketBeat